PMID- 31284074
OWN - NLM
STAT- MEDLINE
DCOM- 20200305
LR  - 20200305
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 215
DP  - 2019 Sep
TI  - The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A pilot 
      randomized placebo controlled trial of colchicine following acute myocardial 
      infarction.
PG  - 62-69
LID - S0002-8703(19)30148-6 [pii]
LID - 10.1016/j.ahj.2019.06.003 [doi]
AB  - Following an acute myocardial infarction (MI), patients with persistently 
      elevated biomarkers of inflammation, in particular C-reactive protein (CRP), are 
      at significantly increased risk of further cardiovascular events. Colchicine is a 
      unique anti-inflammatory medication that has shown promise in reducing such 
      events in patients with stable coronary heart disease. The current study tested 
      the ability of low dose colchicine to reduce CRP levels at 30 days after an acute 
      MI, a key marker of future outcome, and its safety and tolerability in this 
      setting. METHODS: We conducted a randomized, double-blind, trial of low-dose 
      colchicine (0.5 mg daily) or matching placebo in 237 patients admitted with an 
      acute MI. The primary end-point was the proportion of patients with a residual 
      high sensitivity CRP level >/=2 mg/L after 30 days of treatment, a threshold 
      associated with a worse prognosis. RESULTS: At 30-day follow-up, 44% of patients 
      treated with colchicine had a CRP level >/=2 mg/L compared to 50% of those 
      randomized to placebo (P = .35) and the median CRP in patients randomized to 
      colchicine was 1.6 mg/L (interquartile range [IQR] 0.7-3.5) compared to 2.0 mg/L 
      (IQR 0.9-4.0) in patients randomized to placebo (P = .11). The median absolute 
      reduction in CRP levels was -4.3 mg/L (IQR -1.1 to -14.1) among colchicine 
      treated patients and -3.3 mg/L (IQR -0.9 to -14.4, P = .44) in placebo treated 
      patients. The relative reduction was a fall of 78% compared to a fall of 64% 
      (P = .09). Low dose colchicine was well tolerated and did not reduce compliance 
      with other secondary preventative medications at 30-days. CONCLUSION: Treatment 
      with low dose colchicine was safe and well tolerated, but was not associated with 
      a significantly increased likelihood of achieving a CRP level <2 mg/L or lower 
      absolute levels of CRP 30 days after an acute MI.
CI  - Copyright (c) 2019 Elsevier Inc. All rights reserved.
FAU - Hennessy, Thomas
AU  - Hennessy T
AD  - Department of Cardiology, Royal Perth Hospital, Perth and Faculty of Health and 
      Medical Sciences, University of Western Australia; Heart Research Institute, 
      Sydney, Department of Cardiology, Royal Prince Alfred Hospital, Sydney and 
      Faculty of Medicine, University of Sydney.
FAU - Soh, Linda
AU  - Soh L
AD  - Department of Cardiology, Royal Perth Hospital, Perth and Faculty of Health and 
      Medical Sciences, University of Western Australia; Heart Research Institute, 
      Sydney, Department of Cardiology, Royal Prince Alfred Hospital, Sydney and 
      Faculty of Medicine, University of Sydney.
FAU - Bowman, Mitchell
AU  - Bowman M
AD  - Department of Cardiology, Royal Perth Hospital, Perth and Faculty of Health and 
      Medical Sciences, University of Western Australia; Heart Research Institute, 
      Sydney, Department of Cardiology, Royal Prince Alfred Hospital, Sydney and 
      Faculty of Medicine, University of Sydney.
FAU - Kurup, Rahul
AU  - Kurup R
AD  - Department of Cardiology, Royal Perth Hospital, Perth and Faculty of Health and 
      Medical Sciences, University of Western Australia; Heart Research Institute, 
      Sydney, Department of Cardiology, Royal Prince Alfred Hospital, Sydney and 
      Faculty of Medicine, University of Sydney.
FAU - Schultz, Carl
AU  - Schultz C
AD  - Department of Cardiology, Royal Perth Hospital, Perth and Faculty of Health and 
      Medical Sciences, University of Western Australia; Heart Research Institute, 
      Sydney, Department of Cardiology, Royal Prince Alfred Hospital, Sydney and 
      Faculty of Medicine, University of Sydney.
FAU - Patel, Sanjay
AU  - Patel S
AD  - Department of Cardiology, Royal Perth Hospital, Perth and Faculty of Health and 
      Medical Sciences, University of Western Australia; Heart Research Institute, 
      Sydney, Department of Cardiology, Royal Prince Alfred Hospital, Sydney and 
      Faculty of Medicine, University of Sydney.
FAU - Hillis, Graham S
AU  - Hillis GS
AD  - Department of Cardiology, Royal Perth Hospital, Perth and Faculty of Health and 
      Medical Sciences, University of Western Australia; Heart Research Institute, 
      Sydney, Department of Cardiology, Royal Prince Alfred Hospital, Sydney and 
      Faculty of Medicine, University of Sydney. Electronic address: 
      graham.hillis@health.wa.gov.au.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190614
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Biomarkers)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - SML2Y3J35T (Colchicine)
SB  - IM
MH  - Biomarkers/blood
MH  - C-Reactive Protein/metabolism
MH  - Colchicine/*administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Inflammation/blood/*drug therapy/etiology
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/blood/*complications
MH  - Pilot Projects
MH  - Retrospective Studies
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2019/07/10 06:00
MHDA- 2020/03/07 06:00
CRDT- 2019/07/09 06:00
PHST- 2019/01/29 00:00 [received]
PHST- 2019/06/01 00:00 [accepted]
PHST- 2019/07/10 06:00 [pubmed]
PHST- 2020/03/07 06:00 [medline]
PHST- 2019/07/09 06:00 [entrez]
AID - S0002-8703(19)30148-6 [pii]
AID - 10.1016/j.ahj.2019.06.003 [doi]
PST - ppublish
SO  - Am Heart J. 2019 Sep;215:62-69. doi: 10.1016/j.ahj.2019.06.003. Epub 2019 Jun 14.